Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O95372

UPID:
LYPA2_HUMAN

ALTERNATIVE NAMES:
Lysophospholipase II; Palmitoyl-protein hydrolase

ALTERNATIVE UPACC:
O95372; Q7Z4Z2

BACKGROUND:
The enzyme Acyl-protein thioesterase 2, recognized alternatively as Lysophospholipase II and Palmitoyl-protein hydrolase, is pivotal in mediating depalmitoylation of key proteins like ZDHHC6 and HRAS, and exhibits lysophospholipase activity. It specifically targets prostaglandin glycerol esters and 1-arachidonoylglycerol, playing a significant role in lipid signaling pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Acyl-protein thioesterase 2 offers a promising avenue for the development of novel therapeutic approaches, particularly in the realm of lipid metabolism disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.